This is a randomized trial to compare intermittent compression devices with or without
post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for
known or presumed gynecologic malignancies. This trial seeks to determine if there is a
difference in the rate of deep venous thrombosis between these two groups.
To assess the effectiveness of Arixtra in the prophylaxis of deep venous thromboembolism in
gynecologic oncology patients undergoing abdominopelvic surgery.
- All patients undergoing open laparotomy (non-laparoscopic) gynecologic surgery.
- Patients must be competent to self-administer injections, or must have caregivers or
nurses who can perform injections
- Patients must have signed an approved informed consent
- Patients with medical history which requires chronic anticoagulation (i.e. previous
DVT, pulmonary embolism, atrial fibrillation, heart valve replacement)
- Patients with contraindications to anticoagulation (generalized bleeding disorders,
peptic ulcer disease, hemorrhagic stroke, etc)
- Contraindications to placement of ICDs (history of lower extremity venous stasis
- Patients receiving low molecular weight heparin or unfractionated heparin for
- Patients who are unable to receive injections as an outpatient and/or unable to
undergo a doppler ultrasound of the lower extremities
- Renal insufficiency (creatinine clearance < 30 mL/min)
- Patients who have a body weight < 50 kg
- Hypersensitivity to low molecular weight heparin
- Patients who are pregnant or have a positive pregnancy test.
- Patients receiving continuous (indwelling) epidural.